Welcome to our dedicated page for Nervgen Pharma news (Ticker: NGENF), a resource for investors and traders seeking the latest updates and insights on Nervgen Pharma stock.
NervGen Pharma Corp. reports developments as a clinical-stage biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. Company updates center on NVG-291, the CONNECT SCI Study, clinical data in chronic spinal cord injury, FDA interactions, intellectual property activity, and preclinical work in traumatic hearing loss and peripheral nerve injury models.
Recurring corporate news also covers financial results, private placements, warrant amendments, U.S. registration activity, Nasdaq listing milestones, and board or executive leadership changes. The company’s releases connect program progress with capital-market actions and governance updates typical of a development-stage biotechnology issuer.
Summary not available.
NervGen Pharma Corp. (TSX-V: NGEN, OTCQX: NGENF) announced a peer-reviewed study showing that its drug NVG-291-R significantly improves motor and sensory functions in rodent models of severe ischemic stroke, even when treatment starts 7 days post-stroke. Currently, there are no FDA-approved treatments that repair stroke damage. NVG-291 is under a Phase 1 clinical trial, with plans for Phase 1b/2 trials targeting spinal cord injury, Alzheimer’s disease, and multiple sclerosis. This research indicates a potential breakthrough in stroke treatment.
NervGen Pharma Corp. (OTCQX: NGENF) has announced its first clinical trial for NVG-291, targeting spinal cord injury patients, through a partnership with Shirley Ryan AbilityLab. This Phase 1b/2a trial will assess the safety and efficacy of NVG-291 in both acute and chronic patients, beginning in late 2022. Previous animal studies published in Nature and Experimental Neurology have shown NVG-291's potential to improve motor and sensory functions significantly. The trial represents a crucial step in translating these promising preclinical results into patient treatment.